Bibliotecas PUC-SP - Busca Integrada

FGFR Inhibitors in Oncology: Insight on the Management of Toxicities in Clinical Practice

Autor Anuhya Kommalapati, Sri Harsha Tella, Mitesh Borad, Milind Javle, Amit Mahipal
Vydáno v Cancers (2021-06-01)

Biomarkers of TGF-β signaling pathway and prognosis of pancreatic cancer.

Autor Milind Javle, Yanan Li, Dongfeng Tan, Xiaoqun Dong, Ping Chang, Siddhartha Kar, Donghui Li
Vydáno v PLoS ONE (2014-01-01)

Single-cell mRNA profiling reveals transcriptional heterogeneity among pancreatic circulating tumour cells

Autor Morten Lapin, Kjersti Tjensvoll, Satu Oltedal, Milind Javle, Rune Smaaland, Bjørnar Gilje, Oddmund Nordgård
Vydáno v BMC Cancer (2017-05-01)

Fragment size and level of cell-free DNA provide prognostic information in patients with advanced pancreatic cancer

Autor Morten Lapin, Satu Oltedal, Kjersti Tjensvoll, Tove Buhl, Rune Smaaland, Herish Garresori, Milind Javle, Nils Idar Glenjen, Bente Kristin Abelseth, Bjørnar Gilje, Oddmund Nordgård
Vydáno v Journal of Translational Medicine (2018-11-01)

Randomized, phase I/II study of gemcitabine plus IGF-1R antagonist (MK-0646) versus gemcitabine plus erlotinib with and without MK-0646 for advanced pancreatic adenocarcinoma

Autor Reham Abdel-Wahab, Gauri R. Varadhachary, Priya R. Bhosale, Xuemei Wang, David R. Fogelman, Rachna T. Shroff, Michael J. Overman, Robert A. Wolff, Milind Javle
Vydáno v Journal of Hematology & Oncology (2018-05-01)

Immune Checkpoint Inhibitors for Solid Tumors in the Adjuvant Setting: Current Progress, Future Directions, and Role in Transplant Oncology

Autor Karen Abboud, Godsfavour Umoru, Abdullah Esmail, Ala Abudayyeh, Naoka Murakami, Humaid O. Al-Shamsi, Milind Javle, Ashish Saharia, Ashton A. Connor, Sudha Kodali, Rafik M. Ghobrial, Maen Abdelrahim
Vydáno v Cancers (2023-02-01)

584 Phase I/II study to evaluate the safety and tolerability of avelumab in combination with other anti-cancer therapies in patients with advanced malignancies

Autor Aung Naing, Funda Meric-Bernstam, Shubham Pant, Milind Javle, Juhee Song, Anas Alshawa, Bettzy Stephen, Abdulrazzak Zarifa, Jordi Rodon, Yali Yang, Robert A Wolff, Anne Knisely, Van Morris, Jibran Ahmed
Vydáno v Journal for ImmunoTherapy of Cancer (2023-11-01)

Genomic profiling reveals high frequency of DNA repair genetic aberrations in gallbladder cancer

Autor Reham Abdel-Wahab, Timothy A. Yap, Russell Madison, Shubham Pant, Matthew Cooke, Kai Wang, Haitao Zhao, Tanios Bekaii-Saab, Elif Karatas, Lawrence N. Kwong, Funda Meric-Bernstam, Mitesh Borad, Milind Javle
Vydáno v Scientific Reports (2020-12-01)

Corticosteroid-Refractory Myositis After Dual BRAF and MEK Inhibition in a Patient with BRAF V600E-Mutant Metastatic Intrahepatic Cholangiocarcinoma

Autor Timothy P. DiPeri, Mehmet Demirhan, Daniel D. Karp, Siqing Fu, David S. Hong, Vivek Subbiah, Joann Lim, Leomar Y. Ballester, Jean H. Tayar, Maria E. Suarez-Almazor, Milind Javle, Funda Meric-Bernstam
Vydáno v Journal of Immunotherapy and Precision Oncology (2022-02-01)

Randomized phase II study of the Bruton tyrosine kinase inhibitor acalabrutinib, alone or with pembrolizumab in patients with advanced pancreatic cancer

Autor Al B Benson, Anirban Maitra, Milind Javle, Michael Overman, Richard E Davis, Pankaj Vats, Chandan Kumar-Sinha, Lianchun Xiao, Niharika B Mettu, Edwin R Parra, Charles D Lopez, Veerendra Munugalavadla, Priti Patel, Lin Tao, Sattva Neelapu
Vydáno v Journal for ImmunoTherapy of Cancer (2020-05-01)

RAF inhibitor re-challenge therapy in BRAF-aberrant pan-cancers: the RE-RAFFLE study

Autor Blessie Elizabeth Nelson, Jason Roszik, Jibran Ahmed, Carmelia Maria Noia Barretto, Mirella Nardo, Erick Campbell, Amber M Johnson, Sarina A. Piha-Paul, Isabella C. Glitza Oliva, Shiao-Pei Weathers, Maria Cabanillas, Milind Javle, Funda Meric-Bernstam, Vivek Subbiah
Vydáno v Molecular Cancer (2024-03-01)

BRAF v600E–mutant cancers treated with vemurafenib alone or in combination with everolimus, sorafenib, or crizotinib or with paclitaxel and carboplatin (VEM-PLUS) study

Autor Blessie Elizabeth Nelson, Jason Roszik, Filip Janku, David S. Hong, Shumei Kato, Aung Naing, Sarina Piha-Paul, Siqing Fu, Apostolia Tsimberidou, Maria Cabanillas, Naifa Lamki Busaidy, Milind Javle, Lauren Averett Byers, John V. Heymach, Funda Meric-Bernstam, Vivek Subbiah
Vydáno v npj Precision Oncology (2023-02-01)

CRISPR screening identifies BET and mTOR inhibitor synergy in cholangiocarcinoma through serine glycine one carbon

Autor Yan Zhu, Dengyong Zhang, Pooja Shukla, Young-Ho Jung, Prit Benny Malgulwar, Sharmeen Chagani, Medina Colic, Sarah Benjamin, John A. Copland III, Lin Tan, Philip L. Lorenzi, Milind Javle, Jason T. Huse, Jason Roszik, Traver Hart, Lawrence N. Kwong
Vydáno v JCI Insight (2024-01-01)

Safety and Efficacy of Toripalimab in Patients with Cholangiocarcinoma: An Open-Label, Phase 1 Study

Autor Aung Naing, Amit Mahipal, Milind Javle, Judy Wang, Todd M. Bauer, David L. Bajor, Anthony D. Elias, Anthony Shields, Elizabeth Davis, Sant Chawla, Howard Safran, John D. Powderly, Gina D’Amato, Christian F. Meyer, Xiongwen Tang, Sheng Yao, Patricia Keegan
Vydáno v Journal of Immunotherapy and Precision Oncology (2025-01-01)

Mutation profiling in cholangiocarcinoma: prognostic and therapeutic implications.

Autor Chaitanya R Churi, Rachna Shroff, Ying Wang, Asif Rashid, HyunSeon C Kang, Jacqueline Weatherly, Mingxin Zuo, Ralph Zinner, David Hong, Funda Meric-Bernstam, Filip Janku, Christopher H Crane, Lopa Mishra, Jean-Nicholas Vauthey, Robert A Wolff, Gordon Mills, Milind Javle
Vydáno v PLoS ONE (2014-01-01)

Outcomes and Toxicities of Modern Combined Modality Therapy with Atezolizumab Plus Bevacizumab and Radiation Therapy for Hepatocellular Carcinoma

Autor Gohar Shahwar Manzar, Brian Sandeep De, Chike Osita Abana, Sunyoung S. Lee, Milind Javle, Ahmed O. Kaseb, Jean-Nicolas Vauthey, Hop Sanderson Tran Cao, Albert C. Koong, Grace Li Smith, Cullen M. Taniguchi, Emma Brey Holliday, Prajnan Das, Eugene Jon Koay, Ethan Bernard Ludmir
Vydáno v Cancers (2022-04-01)

Phase II study of talazoparib in advanced cancers with BRCA1/2, DNA repair, and PTEN alterations

Autor Sarina A. Piha-Paul, Chieh Tseng, Cheuk Hong Leung, Ying Yuan, Daniel D. Karp, Vivek Subbiah, David Hong, Siqing Fu, Aung Naing, Jordi Rodon, Milind Javle, Jaffer A. Ajani, Kanwal P. Raghav, Neeta Somaiah, Gordon B. Mills, Apostolia M. Tsimberidou, Xiaofeng Zheng, Ken Chen, Funda Meric-Bernstam
Vydáno v npj Precision Oncology (2024-07-01)

Limited Independent Follow-Up with Germline Testing of Variants Detected in BRCA1 and BRCA2 by Tumor-Only Sequencing

Autor Carol J. Nowlen, Molly Daniels, Burak Uzunparmak, Ecaterina E. Ileana Dumbrava, Ying Yuan, Keyur P. Patel, Nadine Rayes, Jacqueline Harkenrider, Chetna Wathoo, Jennifer Veazie, Krystle A. Luna, Wanlin Wang, Chacha Horombe, Milind Javle, Jordi Rodon Ahnert, Timothy A. Yap, Banu Arun, Karen H. Lu, Funda Meric-Bernstam
Vydáno v Journal of Immunotherapy and Precision Oncology (2024-02-01)

Efficacy and safety of autologous tumor-infiltrating lymphocytes in recurrent or refractory ovarian cancer, colorectal cancer, and pancreatic ductal adenocarcinoma

Autor Chantale Bernatchez, Shubham Pant, Rodabe Amaria, Marie-Andree Forget, Milind Javle, Donastas Sakellariou-Thompson, Karen H Lu, Scott Kopetz, Mara B Antonoff, Cara L Haymaker, Ying Yuan, Robert A Wolff, Michael J Overman, Anne Knisely, Amir A Jazaeri, Bryan Fellman, Kelly Rangel, David Vining, Ching-Wei D Tzeng, Kathryn Lito
Vydáno v Journal for ImmunoTherapy of Cancer (2024-02-01)

Implementation of a Novel Web-Based Lesion Selection Tool to Improve Acquisition of Tumor Biopsy Specimens

Autor Mingxuan Xu, Coya Tapia, Joud Hajjar, Sharjeel Sabir, Rivka Colen, Priyadharsini Nagarajan, Phyu P. Aung, Jing Gong, Jordi Rodon, Siqing Fu, Bettzy Stephen, Sinchita Roy-Chowdhuri, Hung Le, Vincent Yang, Abdulrazzak Zarifa, Mohamed Elsayed Abdelsalam, Anuja Jhingran, Milind Javle, Shubham Pant, Brett Carter, Denai R. Milton, Ryan Sun, Daniel D. Karp, Eugene Jon Koay, Yali Yang, Ignacio I. Wistuba, Patrick Hwu, Funda Meric-Bernstam, Aung Naing
Vydáno v Journal of Immunotherapy and Precision Oncology (2021-05-01)